Literature DB >> 11762935

Selective lymphocyte chemokine receptor expression in the rheumatoid joint.

J H Ruth1, J B Rottman, K J Katschke, S Qin, L Wu, G LaRosa, P Ponath, R M Pope, A E Koch.   

Abstract

OBJECTIVE: In patients with rheumatoid arthritis (RA), chemokines and their receptors are important for lymphocyte trafficking into the inflamed joint. This study was undertaken to characterize the expression of chemokine receptors CCR1, CCR2, CCR3, CCR4, CCR5, CCR6, CXCR3, and CX3CR1 in normal (NL) peripheral blood (PB), RA PB, and RA synovial fluid (SF).
METHODS: Using flow cytometry, immunohistochemistry, and 2-color immunofluorescence, we defined the expression of chemokine receptors on CD3+ T lymphocytes in RA synovial tissue (ST), RA SF, RA PB, and NL PB.
RESULTS: The percentage of CD3+ lymphocytes expressing CCR2, CCR4, CCR5, and CX3CR1 was significantly elevated in RA PB compared with that in NL PB, while the percentage of CD3+ lymphocytes expressing CCR5 was significantly enhanced in RA SF compared with that in NL and RA PB. In contrast, similar percentages of CD3+ lymphocytes in NL PB, RA PB, and RA SF expressed CCR6 and CXCR3. Immunohistochemistry of RA ST showed lymphocyte expression of CCR4, and 2-color immunofluorescence staining revealed RA ST CD3+ lymphocytes intensely immunoreactive for CXCR3, suggesting that these 2 receptors may be particularly important for CD3+ lymphocyte trafficking to the inflamed joint. In comparisons of chemokine receptor expression on naive (CD45RA+) and memory (CD45RO+) CD3+ lymphocytes, there were greater percentages of memory CD3+/CD4+ lymphocytes expressing CCR4, CCR5, and CXCR3 than naive CD3+/CD4+ lymphocytes in RA PB and RA SF, and greater percentages of memory CD3+/CD8+ lymphocytes expressing CCR4, CCR5, and CXCR3 than naive CD3+/CD8+ lymphocytes in RA SF, suggesting receptor up-regulation upon lymphocyte activation. In contrast, percentages of CD3+/CD8+ memory lymphocytes expressing CX3CR1 were significantly less than percentages of naive CD3+/CD8+ lymphocytes in RA PB, suggesting that this receptor may be down-regulated upon lymphocyte activation. A major difference between the RA PB and NL PB groups was significantly more CCR4+ memory leukocytes and memory CCR5+/ CD3+/CD8+ lymphocytes in RA PB than NL PB, further suggesting that these receptors may be particularly important for lymphocyte homing to the RA joint.
CONCLUSION: These results identify CCR4, CCR5, CXCR3, and CX3CR1 as critical chemokine receptors in RA.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11762935     DOI: 10.1002/1529-0131(200112)44:12<2750::aid-art462>3.0.co;2-c

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  48 in total

1.  Decreased Th17 and antigen-specific humoral responses in CX₃ CR1-deficient mice in the collagen-induced arthritis model.

Authors:  Teresa K Tarrant; Peng Liu; Rishi R Rampersad; Denise Esserman; Lisa R Rothlein; Roman G Timoshchenko; Marcus W McGinnis; David J Fitzhugh; Dhavalkumar D Patel; Alan M Fong
Journal:  Arthritis Rheum       Date:  2012-05

2.  CCR5 blockade is well tolerated and induces changes in the tissue distribution of CCR5+ and CD25+ T cells in healthy, SIV-uninfected rhesus macaques.

Authors:  Jessica E Taaffe; Steven E Bosinger; Gregory Q Del Prete; James G Else; Sarah Ratcliffe; Christopher D Ward; Thi Migone; Mirko Paiardini; Guido Silvestri
Journal:  J Med Primatol       Date:  2011-11-14       Impact factor: 0.667

3.  Expression and function of CXCL16 in a novel model of gout.

Authors:  Jeffrey H Ruth; Monica D Arendt; M Asif Amin; Salahuddin Ahmed; Hubert Marotte; Bradley J Rabquer; Charles Lesch; Solhee Lee; Alisa E Koch
Journal:  Arthritis Rheum       Date:  2010-08

4.  Peripheral blood T4 cell surface CCR5 density as a marker of activity in rheumatoid arthritis treated with anti-CD20 monoclonal antibody.

Authors:  Pierre Portalès; Sylvie Fabre; Thierry Vincent; Caroline Desmetz; Brigitte Réant; Danièle Noël; Jacques Clot; Christian Jorgensen; Pierre Corbeau
Journal:  Immunology       Date:  2009-03-26       Impact factor: 7.397

5.  TGF-β type II receptor/MCP-5 axis: at the crossroad between joint and growth plate development.

Authors:  Lara Longobardi; Tieshi Li; Timothy J Myers; Lynda O'Rear; Huseyin Ozkan; Ying Li; Clara Contaldo; Anna Spagnoli
Journal:  Dev Cell       Date:  2012-07-17       Impact factor: 12.270

6.  CCR2 deficiency in monocytes impairs angiogenesis and functional recovery after ischemic stroke in mice.

Authors:  Jordi Pedragosa; Francesc Miró-Mur; Amaia Otxoa-de-Amezaga; Carles Justicia; Francisca Ruíz-Jaén; Peter Ponsaerts; Manolis Pasparakis; Anna M Planas
Journal:  J Cereb Blood Flow Metab       Date:  2020-03-09       Impact factor: 6.200

7.  Role of the C-C chemokine receptor-2 in a murine model of injury-induced osteoarthritis.

Authors:  L Longobardi; J D Temple; L Tagliafierro; H Willcockson; A Esposito; N D'Onofrio; E Stein; T Li; T J Myers; H Ozkan; M L Balestrieri; V Ulici; R F Loeser; A Spagnoli
Journal:  Osteoarthritis Cartilage       Date:  2016-11-14       Impact factor: 6.576

8.  Increased expression of CCL18, CCL19, and CCL17 by dendritic cells from patients with rheumatoid arthritis, and regulation by Fc gamma receptors.

Authors:  T R D J Radstake; R van der Voort; M ten Brummelhuis; M de Waal Malefijt; M Looman; C G Figdor; W B van den Berg; P Barrera; G J Adema
Journal:  Ann Rheum Dis       Date:  2004-08-26       Impact factor: 19.103

9.  Monocytes/macrophages express chemokine receptor CCR9 in rheumatoid arthritis and CCL25 stimulates their differentiation.

Authors:  Caroline Schmutz; Alison Cartwright; Helen Williams; Oliver Haworth; John H H Williams; Andrew Filer; Mike Salmon; Christopher D Buckley; Jim Middleton
Journal:  Arthritis Res Ther       Date:  2010-08-25       Impact factor: 5.156

10.  The production of CXCR3-agonistic chemokines by synovial fibroblasts from patients with rheumatoid arthritis.

Authors:  Akiko Ueno; Masahiro Yamamura; Mitsuhiro Iwahashi; Akira Okamoto; Tetsushi Aita; Norio Ogawa; Hirofumi Makino
Journal:  Rheumatol Int       Date:  2004-03-05       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.